REBOA in Non-Trauma Cardiac Arrest Heroic Rescue or Futile Effort
Abstract
Resuscitative endovascular balloon occlusion of the aorta (REBOA) has emerged as a novel endovascular intervention with potential applications beyond its established role in traumatic hemorrhagic shock. In recent years, interest has grown in the use of REBOA as an adjunctive therapy during non traumatic cardiac arrest, driven by the need to improve perfusion to vital organs during cardiopulmonary resuscitation (CPR). Despite remarkable advances in resuscitation science, survival rates following out of hospital cardiac arrest remain low, and neurological outcomes among survivors are often poor. Consequently, considerable research efforts have focused on strategies that may enhance coronary and cerebral blood flow during resuscitation and improve the likelihood of successful recovery.
The physiological rationale for REBOA in cardiac arrest is compelling. During conventional CPR, chest compressions generate only a fraction of normal cardiac output, resulting in limited forward blood flow and suboptimal perfusion of critical organs. Coronary and cerebral perfusion pressures are among the most important determinants of successful resuscitation, as adequate blood flow to the heart and brain is essential for achieving return of spontaneous circulation and preserving neurological function. By inflating a balloon within the descending thoracic aorta, REBOA temporarily occludes distal blood flow and redirects the limited circulation generated by chest compressions toward the heart, brain, and upper body. This redistribution of blood flow has the potential to increase proximal aortic pressure, improve coronary perfusion pressure, enhance cerebral oxygen delivery, and support more effective resuscitation efforts.
Preclinical investigations have provided encouraging evidence supporting this concept. Animal studies have consistently demonstrated that aortic occlusion during cardiac arrest can increase systemic arterial pressures, improve coronary perfusion, and enhance cerebral blood flow during CPR. Experimental models have also shown higher rates of return of spontaneous circulation and improved short term hemodynamic parameters when REBOA is incorporated into advanced resuscitation protocols. These findings generated much enthusiasm for translating the technique into human cardiac arrest management.
Early clinical experiences have similarly suggested that REBOA is technically feasible in selected patients experiencing non traumatic cardiac arrest. Small observational studies and pilot investigations have reported successful deployment during active resuscitation, with measurable improvements in hemodynamic variables such as end tidal carbon dioxide levels, arterial blood pressure, and coronary perfusion pressure. These physiological benefits support the theoretical premise that aortic occlusion may augment the effectiveness of conventional resuscitative measures. However, improvements in surrogate physiological markers do not necessarily translate into meaningful patient centered outcomes such as survival to hospital discharge or favorable neurological recovery.
Recent randomized evidence has provided a more cautious perspective. The 2026 REBOARREST trial, which evaluated prehospital REBOA in combination with advanced life support for patients with non traumatic out of hospital cardiac arrest, demonstrated that the procedure was operationally feasible and could be integrated into prehospital resuscitation workflows by appropriately trained teams. However, despite its physiological effects, the study did not demonstrate a statistically significant improvement in sustained return of spontaneous circulation compared with advanced life support alone. These findings underscore the distinction between hemodynamic optimization and clinically meaningful outcome improvement, highlighting the complexity of translating promising physiological interventions into survival benefits.
Several factors may explain the discrepancy between physiological improvement and clinical outcomes. Cardiac arrest is a multifactorial condition influenced by the underlying cause of arrest, duration of no flow and low flow states, quality of CPR, timeliness of defibrillation, post resuscitation care, and the extent of ischemic injury before intervention. While REBOA may improve blood flow distribution during resuscitation, it cannot reverse prolonged ischemia, severe metabolic derangements, or irreversible organ damage that may already be present. Furthermore, procedural delays associated with vascular access and device deployment may offset potential benefits if not performed rapidly and efficiently.
The practical implementation of REBOA during cardiac arrest also presents important logistical and technical challenges. Successful deployment requires expertise in femoral arterial access, familiarity with endovascular techniques, and access to specialized equipment. Ultrasound guided vascular access is often necessary to improve procedural success and minimize complications, particularly in patients undergoing active CPR. In addition, operators must possess a detailed understanding of balloon positioning, inflation protocols, and complication management. Potential adverse events include vascular injury, arterial dissection, limb ischemia, distal organ hypoperfusion, thromboembolic complications, and reperfusion injury following balloon deflation.
Given these considerations, current evidence does not support the routine use of REBOA in non traumatic cardiac arrest. Rather, the intervention should be regarded as an investigational or highly specialized rescue adjunct reserved for carefully selected patients within structured clinical programs. Appropriate implementation requires systems with experienced operators, ultrasound guided femoral arterial access capability, standardized patient selection criteria, predefined stopping rules, comprehensive device governance, and robust data collection infrastructure. Such programs should be integrated within broader quality improvement and research frameworks to ensure ongoing evaluation of safety and effectiveness.
Importantly, REBOA must never distract from or delay established evidence based resuscitation interventions. High quality CPR remains the foundation of cardiac arrest management and continues to be the most important determinant of perfusion during resuscitation. Rapid defibrillation for shockable rhythms, effective airway and ventilation management, timely administration of vasoactive medications, identification and treatment of reversible causes, and coordinated post arrest care remain essential priorities. Similarly, patients who meet criteria for extracorporeal cardiopulmonary resuscitation should be considered for early activation of extracorporeal support pathways, as current evidence suggests that extracorporeal strategies may offer greater potential for survival benefit in selected populations.
As resuscitation science continues to evolve, REBOA represents an innovative approach that challenges traditional concepts of cardiac arrest management. Its ability to improve central hemodynamics and organ perfusion during CPR makes it an attractive area of ongoing investigation. However, enthusiasm must be balanced by rigorous evaluation of clinical outcomes, procedural risks, resource requirements, and system level feasibility. Future research should focus on identifying patient populations most likely to benefit, optimizing deployment techniques, refining timing strategies, and evaluating integration with advanced resuscitation modalities such as extracorporeal cardiopulmonary resuscitation. Until stronger evidence emerges, REBOA should remain a specialized intervention used within carefully controlled protocols rather than a routine component of standard cardiac arrest care.
Introduction
Non traumatic cardiac arrest remains one of the most formidable challenges in emergency and critical care medicine. Despite significant advances in resuscitation science, including widespread implementation of high quality cardiopulmonary resuscitation (CPR), early defibrillation, evidence based advanced cardiac life support protocols, targeted post arrest care, and improvements in systems of emergency response, survival rates remain disappointingly low. Even among patients who achieve return of spontaneous circulation, many experience substantial neurological injury resulting from prolonged cerebral hypoperfusion and ischemia. Consequently, improving both survival and neurologic outcomes remains a major priority in contemporary resuscitation research.
One of the fundamental limitations of conventional resuscitation is the inability of chest compressions to generate adequate circulatory support. Even when performed optimally, CPR produces only a fraction of normal cardiac output, typically ranging from approximately 20 to 30 percent of baseline physiologic blood flow. This limited circulation must simultaneously perfuse all major organ systems, including the heart, brain, kidneys, liver, and peripheral tissues. As a result, critical organs such as the myocardium and central nervous system often receive insufficient blood flow to sustain cellular function and facilitate recovery. In many cases, inadequate coronary and cerebral perfusion pressure contributes directly to failed resuscitation efforts and poor neurological outcomes.
These physiological limitations have prompted investigators to explore adjunctive interventions capable of enhancing perfusion during cardiac arrest. One such intervention is resuscitative endovascular balloon occlusion of the aorta, commonly referred to as REBOA. Originally developed as a damage control strategy for patients experiencing severe hemorrhagic shock, particularly those with noncompressible torso hemorrhage, REBOA provides temporary endovascular control of the aorta to maintain perfusion of vital organs while definitive treatment is pursued. The procedure involves percutaneous or surgical access to the common femoral artery, followed by advancement of a specialized balloon catheter into the aorta under imaging or anatomical guidance. Inflation of the balloon creates temporary occlusion of distal aortic blood flow, thereby increasing proximal arterial pressure and redirecting circulation toward the heart and brain.
In trauma patients with life threatening hemorrhage, the primary objective of REBOA is to reduce distal blood loss while preserving perfusion to critical organs. In the context of non traumatic cardiac arrest, however, the therapeutic rationale differs substantially. There is no active hemorrhage requiring vascular control. Instead, the proposed benefit lies in altering hemodynamic distribution during resuscitation. By occluding the descending aorta, REBOA may redirect the limited blood flow generated by chest compressions toward the coronary and cerebral circulations. This redistribution has the potential to increase coronary perfusion pressure, improve myocardial oxygen delivery, enhance the likelihood of return of spontaneous circulation, and support cerebral perfusion during prolonged resuscitative efforts.
The physiological basis for this approach is compelling. Coronary perfusion pressure is a critical determinant of successful resuscitation, and numerous studies have demonstrated a strong association between higher coronary perfusion pressures and increased rates of return of spontaneous circulation. Similarly, maintaining cerebral blood flow is essential for preserving neurological function and minimizing ischemic brain injury. By selectively prioritizing blood flow to these vital organs, REBOA has emerged as a potentially valuable adjunct in cardiac arrest management.
Experimental and animal studies have provided preliminary support for this concept. Investigators have reported improvements in central aortic pressure, coronary perfusion pressure, cerebral blood flow, and rates of return of spontaneous circulation following aortic occlusion during cardiac arrest. Early human feasibility studies have also demonstrated that REBOA can be deployed during resuscitation by trained teams, suggesting that integration into advanced resuscitation protocols may be technically achievable in selected settings.
Nevertheless, physiological plausibility alone is insufficient to justify widespread clinical adoption. The key question is whether the hemodynamic benefits observed in experimental models translate into meaningful improvements in patient centered outcomes, including survival to hospital discharge and favorable neurological recovery. Achieving higher perfusion pressures is valuable only if it ultimately improves long term outcomes rather than merely prolonging resuscitation efforts without meaningful recovery.
Several practical and clinical concerns must also be considered. REBOA is an invasive procedure that requires vascular access, specialized equipment, and appropriately trained personnel. Deployment during cardiac arrest may introduce procedural delays that compete with established resuscitation priorities such as uninterrupted chest compressions, timely defibrillation, airway management, and administration of evidence based pharmacologic therapies. Any intervention that distracts from or delays these core elements of resuscitation must demonstrate substantial clinical benefit to justify its implementation.
In addition, REBOA carries inherent procedural risks. Potential complications include arterial injury, vascular dissection, thrombosis, limb ischemia, distal organ hypoperfusion, bleeding, and reperfusion injury following balloon deflation. These risks may be amplified in critically ill cardiac arrest patients, particularly when vascular access is obtained under emergent conditions. The balance between potential benefits and procedural harms therefore remains a central consideration in evaluating the role of REBOA in non traumatic cardiac arrest.
Current research is increasingly focused on defining optimal patient selection criteria, timing of deployment, duration of aortic occlusion, and integration with other advanced resuscitative technologies such as extracorporeal cardiopulmonary resuscitation. Ongoing clinical trials and observational studies seek to determine whether REBOA can improve survival and neurological outcomes beyond those achieved with standard advanced cardiac life support alone.
In summary, resuscitative endovascular balloon occlusion of the aorta represents an innovative and physiologically appealing approach to addressing one of the major limitations of conventional cardiopulmonary resuscitation. By redirecting blood flow toward the heart and brain during cardiac arrest, REBOA has the potential to enhance coronary and cerebral perfusion when these organs are most vulnerable to ischemic injury. However, despite promising physiological and preliminary clinical data, important questions remain regarding efficacy, safety, feasibility, and overall impact on patient outcomes. Until robust clinical evidence becomes available, the role of REBOA in non traumatic cardiac arrest should be viewed as an evolving area of investigation rather than an established standard of care.
Physiologic Rationale
Coronary perfusion pressure is closely linked to successful resuscitation. During CPR, diastolic aortic pressure and right atrial pressure determine the pressure gradient available to perfuse the myocardium. If coronary perfusion is inadequate, defibrillation and vasopressors are less likely to restore organized circulation.
Zone 1 aortic occlusion during CPR creates a smaller effective vascular bed. Blood generated by chest compressions is preferentially directed to the heart, brain, and upper body. Animal studies have shown increases in proximal aortic pressure, coronary perfusion pressure, and cerebral perfusion surrogates after balloon inflation.
The problem is that hemodynamic improvement is a surrogate endpoint. Aortic occlusion may increase proximal pressure while simultaneously causing visceral, renal, spinal, and lower-extremity ischemia. It can also create logistical delays during a time-sensitive resuscitation. The intervention must therefore be judged by survival and neurologic outcome, not only by pressure curves, end-tidal carbon dioxide, or transient return of spontaneous circulation.
Current Evidence
The evidence base has evolved from animal models and small case series to randomized clinical testing. Preclinical studies support the physiologic mechanism. Early human series showed that REBOA placement during non-traumatic cardiac arrest was technically feasible in selected systems and could be performed during active resuscitation. Some series reported ROSC after REBOA, but sample sizes were small, patient selection was narrow, and survival with favorable neurologic outcome remained inconsistent.
The most important recent evidence is REBOARREST. This international, multicenter, open-label, pragmatic randomized trial evaluated prehospital REBOA as an adjunct to advanced life support in non-traumatic out-of-hospital cardiac arrest. Sustained ROSC was similar between REBOA plus ALS and ALS alone. The study supports feasibility in expert systems but does not support routine deployment as a standard cardiac-arrest intervention.
Other randomized work remains ongoing or protocol-stage. These studies are important because the clinical effect may vary by system, operator experience, time from collapse, arrest etiology, rhythm, and integration with mechanical CPR or ECPR pathways. Until more data mature, the evidence does not justify broad adoption outside research or carefully governed programs.
Table 1. Evidence Hierarchy for REBOA in Non-Traumatic Cardiac Arrest
| Evidence type | What it shows | What it does not prove | Publication implication |
| Animal models | REBOA can increase proximal aortic pressure and coronary perfusion pressure during CPR | Human survival benefit or neurologic benefit | Useful for mechanism only |
| Case reports and small series | Placement can be feasible in selected expert systems; ROSC may occur | Generalizable efficacy, safety, or cost-effectiveness | Hypothesis-generating |
| Retrospective comparisons | Possible hemodynamic or ROSC signals | Causal benefit due to selection bias and confounding | Interpret cautiously |
| REBOARREST randomized trial | Feasible prehospital deployment; no significant sustained ROSC improvement | Definitive exclusion of benefit in every subgroup or system | Strong reason against routine implementation |
| Ongoing trials and registries | May refine patient selection and protocol design | Current standard-of-care status | Needed before broader adoption |
Patient Selection
If REBOA is considered, selection should be narrow. A plausible candidate is an adult with witnessed non-traumatic cardiac arrest, immediate bystander CPR, short no-flow interval, persistent arrest despite high-quality advanced life support, and a potentially reversible cause. The system must have an operator capable of rapid ultrasound-guided common femoral arterial access without compromising CPR quality.
Selection should generally exclude unwitnessed arrest with prolonged no-flow time, prolonged low-flow time without signs of viability, terminal illness, known severe neurologic baseline limitation, suspected aortic dissection, known aortic aneurysm or prior aortic repair, severe peripheral arterial disease, prior femoral vascular reconstruction, inability to obtain common femoral arterial access, traumatic cardiac arrest managed by a trauma algorithm, and situations in which REBOA would delay a more definitive intervention.
Initial rhythm may matter. Patients with shockable rhythms and suspected cardiac etiology may have a more plausible path to meaningful recovery than patients with prolonged asystole and no reversible cause. However, no validated REBOA-specific selection rule exists for non-traumatic cardiac arrest.
Technical and Procedural Considerations
Zone 1 occlusion is the relevant location for non-traumatic cardiac arrest because the goal is proximal perfusion augmentation. Zone 3 occlusion is used for some hemorrhage scenarios but does not provide the same coronary and cerebral perfusion rationale.
The procedure requires reliable common femoral arterial access, preferably ultrasound-guided. Placement should not interrupt compressions. If fluoroscopy is not available, catheter depth must be guided by measured insertion length, device markings, protocolized positioning, and post-placement confirmation when feasible. Misplacement can reduce benefit or increase harm.
Inflation time must be tracked from the moment of occlusion. Complete Zone 1 occlusion should be treated as a time-limited maneuver. Prolonged occlusion increases risk of visceral, renal, spinal, and lower-extremity ischemia. If ROSC occurs, the team must have a plan for gradual deflation, hemodynamic monitoring, reperfusion effects, and transition to definitive care.
A REBOA attempt should have a stopping rule. If access cannot be obtained rapidly, if CPR quality deteriorates, if the patient meets termination criteria, or if a more definitive pathway such as ECPR is available and time-sensitive, REBOA should not continue as a procedural distraction.
Complications and Monitoring
REBOA complications fall into three broad categories: access injury, occlusion injury, and resuscitation-system harm.
Access complications include failed cannulation, arterial puncture complications, dissection, thrombosis, embolization, pseudoaneurysm, hematoma, retroperitoneal bleeding, limb ischemia, and need for vascular repair. These risks may be greater during CPR because pulses are absent, anatomy is compressed, and procedural conditions are chaotic.
Occlusion complications include renal ischemia, mesenteric ischemia, hepatic ischemia, spinal cord ischemia, lower-extremity ischemia, reperfusion acidosis, hyperkalemia, hypotension during deflation, and inflammatory reperfusion injury. Balloon overinflation, rupture, migration, or malposition may add additional risk.
System-level harm may be the most underappreciated problem. If REBOA delays CPR, defibrillation, epinephrine, airway management, reversible-cause treatment, cath lab activation, thrombolysis for suspected massive pulmonary embolism, or ECPR activation, the intervention may worsen outcomes despite improving proximal pressure.
Table 2. Practical Risk Review Before REBOA in Non-Traumatic Cardiac Arrest
| Domain | Favorable feature | Concerning feature |
| Arrest circumstances | Witnessed arrest, immediate CPR, short no-flow time | Unwitnessed arrest, prolonged no-flow time, prolonged low-flow time |
| Arrest physiology | Refractory VF/pVT or potentially reversible PEA | Prolonged asystole without reversible cause |
| System capability | Trained operator, ultrasound, protocol, registry, surgical or vascular backup | Rare use, no credentialing, no data capture, no post-ROSC plan |
| Access feasibility | Ultrasound-identifiable common femoral artery | Severe PAD, prior femoral graft, anatomy preventing rapid access |
| Aortic risk | No known aortic disease | Suspected dissection, aneurysm, prior aortic repair or stent graft |
| Competing pathway | REBOA does not delay ECPR, PCI, thrombolysis, or other definitive care | REBOA distracts from a time-sensitive definitive intervention |
| Ethical governance | Protocolized emergency exception, QI review, reporting | Ad hoc use without oversight or stopping rules |
Table 3. Complications and Monitoring
| Complication category | Examples | Monitoring or mitigation |
| Access injury | Hematoma, retroperitoneal bleed, arterial dissection, thrombosis, embolization, pseudoaneurysm, limb ischemia | Ultrasound access, trained operator, vascular backup, distal perfusion checks after ROSC |
| Occlusion injury | Renal, mesenteric, hepatic, spinal, and lower-extremity ischemia | Track occlusion time, minimize complete Zone 1 duration, monitor lactate, potassium, pH, renal function |
| Deflation injury | Hypotension, acidosis, hyperkalemia, reperfusion instability | Gradual deflation when feasible, vasopressor readiness, serial blood gases and electrolytes |
| Device problems | Malposition, balloon rupture, migration, overinflation | Follow device instructions for use, confirm position when feasible, document inflation volume and time |
| System harm | Delayed CPR, defibrillation, ECPR, PCI, thrombolysis, or reversible-cause treatment | Role assignment, simulation, stopping rules, case review |
Relationship to ECPR, Mechanical CPR, and ACLS
REBOA should be viewed as an adjunct to CPR, not a replacement for advanced life support. It does not oxygenate blood, unload the heart, treat coronary occlusion, remove pulmonary embolus, correct severe hyperkalemia, reverse toxicity, or provide sustained circulatory support.
ECPR is a different intervention. It can provide oxygenation and circulatory support for selected patients with refractory cardiac arrest when rapidly deployed by an experienced system. REBOA may theoretically bridge to ECPR in some settings, but this should not delay cannulation or team activation. If a patient meets local ECPR criteria, REBOA should be integrated into that pathway only if it accelerates rather than complicates definitive support.
Mechanical CPR may help maintain compression quality during transport, procedures, or hazardous conditions, but it is not recommended for routine use in all adult arrests. If mechanical CPR is used with REBOA, interruptions during deployment and vascular access must be minimized.
ACLS medications remain standard resuscitation tools. REBOA should not be framed as reducing the need for epinephrine or antiarrhythmics unless supported by protocol-specific data. The more appropriate statement is that REBOA may alter drug distribution volume and proximal perfusion, but the clinical importance of that effect remains uncertain.
Regulatory and Device-Labeling Considerations
REBOA devices are medical devices, not drugs. Their labeled indications generally address temporary occlusion of large vessels, blood pressure monitoring, and hemorrhage control, depending on the specific device. Non-traumatic cardiac arrest resuscitation should not be presented as an established labeled outcome indication unless a device-specific label explicitly supports that claim.
Institutions using REBOA in non-traumatic cardiac arrest should review the current device instructions for use, credentialing requirements, emergency-use policies, sterile technique, sheath size, imaging requirements, balloon inflation limits, pressure monitoring, and adverse-event reporting. Device availability does not equal evidence-based indication.
Ethics and Governance
Non-traumatic cardiac arrest patients cannot consent. REBOA in this setting should therefore be governed by an institutional protocol, emergency exception process when applicable, prospective data capture, and regular review of outcomes and complications. Community consultation may be required for formal research depending on jurisdiction and study design.
Ethical implementation also requires stopping rules. An invasive procedure can prolong resuscitation without improving meaningful recovery. Teams should define when REBOA will be attempted, when it will be abandoned, how long occlusion can continue, and when ongoing resuscitation is no longer appropriate.
Equity matters. Advanced interventions tend to cluster in well-resourced systems. If REBOA is offered, selection criteria should be transparent and clinically justified rather than dependent on operator enthusiasm or patient location alone.
Practical Position in 2026
REBOA in non-traumatic cardiac arrest is neither clearly heroic nor automatically futile. It is a technically feasible, physiologically plausible, invasive adjunct that has not demonstrated routine clinical benefit in randomized evidence.
The appropriate role in 2026 is limited. REBOA may be considered within research protocols, registries, or mature resuscitation systems with trained operators and strict governance. It should not be added casually to standard cardiac-arrest care. It should not be used when it delays proven interventions. It should not be marketed as a rescue therapy on the basis of ROSC alone.
The key outcome is survival with favorable neurologic function. Future research should focus on selection criteria, timing, integration with ECPR, safe occlusion duration, partial occlusion strategies, complication reporting, and long-term neurologic outcomes.
Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) has emerged as a promising intervention in the management of cardiac arrest due to its potential to enhance the physiological effectiveness of cardiopulmonary resuscitation (CPR). By temporarily occluding the aorta, REBOA redistributes blood flow toward the heart and brain, increasing proximal aortic pressure and potentially improving coronary and cerebral perfusion during resuscitative efforts. Given that inadequate myocardial and cerebral blood flow are major determinants of poor outcomes during cardiac arrest, the physiological rationale supporting REBOA has generated considerable interest among emergency medicine, critical care, trauma, and prehospital care specialists.
The theoretical benefits of REBOA in non traumatic cardiac arrest are grounded in established principles of resuscitation physiology. During conventional CPR, cardiac output is significantly reduced compared with normal physiological conditions, resulting in limited perfusion of vital organs. Coronary perfusion pressure is a key predictor of return of spontaneous circulation (ROSC), while cerebral perfusion is closely linked to neurological recovery and long term functional outcomes. By inflating a balloon within the descending thoracic aorta, REBOA creates a mechanical barrier that redirects blood flow to the upper body, thereby increasing perfusion pressure to the heart and brain. Experimental and animal studies have demonstrated improvements in hemodynamic parameters, including increased aortic pressure, enhanced coronary blood flow, and improved cerebral circulation during cardiac arrest.
These encouraging physiological findings have fueled enthusiasm for the integration of REBOA into advanced cardiac arrest management protocols. Early observational studies and pilot investigations suggested that the technique could be performed in selected patients and might improve key resuscitation metrics. As a result, some experts proposed that REBOA could serve as an adjunctive intervention in cases where conventional advanced life support measures fail to achieve adequate circulation. The concept was particularly appealing for patients with refractory cardiac arrest, in whom therapeutic options remain limited and survival rates are generally poor.
Despite these physiological advantages, translating hemodynamic improvements into meaningful clinical outcomes has proven far more challenging. While enhanced perfusion during CPR is theoretically desirable, the ultimate goal of any cardiac arrest intervention is not merely the restoration of circulation but the achievement of survival with favorable neurological function. Improvements in surrogate physiological markers do not necessarily result in improved patient centered outcomes, and this distinction is critical when evaluating novel resuscitation technologies.
A major development in this field came with the publication of the 2026 REBOARREST trial, which represents one of the most important contemporary evaluations of REBOA in non traumatic out of hospital cardiac arrest. The trial demonstrated that prehospital REBOA deployment was technically feasible and could be incorporated into advanced resuscitation workflows in experienced emergency medical systems. Importantly, however, the study did not demonstrate a statistically significant improvement in sustained return of spontaneous circulation when compared with standard advanced life support alone. These findings challenge earlier assumptions that physiological enhancement would necessarily translate into improved clinical outcomes.
The implications of the REBOARREST trial extend beyond the specific outcome measures evaluated. The results underscore the importance of maintaining scientific rigor when assessing emerging technologies in resuscitation medicine. While procedural feasibility and short term hemodynamic improvements are valuable measures during early investigation, they should not be mistaken for evidence of clinical effectiveness. The absence of a clear improvement in sustained ROSC suggests that the relationship between perfusion augmentation and survival outcomes may be more complex than initially anticipated.
Furthermore, the use of REBOA introduces practical considerations that must be carefully weighed against its potential benefits. Successful deployment requires specialized equipment, highly trained personnel, vascular access expertise, and strict adherence to procedural protocols. The intervention also carries risks, including vascular injury, limb ischemia, bleeding complications, balloon malposition, and delays in other resuscitative measures. These challenges may be particularly relevant in prehospital environments where resources, personnel, and procedural opportunities are limited.
Current evidence therefore does not support the routine incorporation of REBOA into standard treatment algorithms for non traumatic cardiac arrest. Instead, its use should remain restricted to carefully selected patients within research settings or highly protocolized clinical programs that possess the necessary expertise, training, and quality assurance infrastructure. Such an approach allows continued evaluation of the technology while minimizing the risk of widespread adoption before definitive evidence of benefit is established.
Future research should focus on identifying patient populations that may derive the greatest benefit from REBOA, optimizing timing of deployment, refining procedural techniques, and integrating the intervention with other advanced resuscitation strategies such as extracorporeal cardiopulmonary resuscitation. Equally important is the selection of clinically meaningful outcome measures. Success should be defined not by procedural accomplishment, transient increases in blood pressure, or short term restoration of circulation alone, but by survival to hospital discharge and preservation of neurological function.
In conclusion, REBOA represents an innovative and physiologically compelling adjunct to cardiac arrest resuscitation. Its ability to augment proximal aortic pressure and enhance coronary and cerebral perfusion provides a strong mechanistic rationale for continued investigation. However, current clinical evidence, including findings from the 2026 REBOARREST trial, does not justify its broad routine use in non traumatic cardiac arrest. Until robust data demonstrate improvements in neurologically intact survival, REBOA should remain an investigational or highly specialized rescue intervention employed within experienced systems committed to evidence based practice and ongoing clinical evaluation.
References
American Heart Association. (2025). Highlights of the 2025 American Heart Association guidelines for CPR and ECC.
Brede, J. R., Farbu, B. H., Gamberini, L., Thorsen, K., Rehn, M., Rognås, L., et al. (2026). Prehospital resuscitative endovascular balloon occlusion of the aorta in non-traumatic out-of-hospital cardiac arrest (REBOARREST): An international, multicentre, open label, pragmatic, randomised, controlled trial. Critical Care. https://doi.org/10.1186/s13054-026-06057-y
Brenner, M., Bulger, E. M., Perina, D. G., Henry, S., Kang, C. S., Rotondo, M. F., et al. (2017). Joint statement from the American College of Surgeons Committee on Trauma and the American College of Emergency Physicians regarding the clinical use of resuscitative endovascular balloon occlusion of the aorta. Journal of Trauma and Acute Care Surgery, 82(3), 605-608.
Daley, J., Morrison, J. J., Sather, J., & Hile, L. (2017). The role of resuscitative endovascular balloon occlusion of the aorta as an adjunct to ACLS in non-traumatic cardiac arrest. American Journal of Emergency Medicine, 35(5), 731-736.
Dogan, E. M., Beskow, L., Calais, F., Hörer, T. M., Axelsson, B., & Nilsson, K. F. (2016). Resuscitative endovascular balloon occlusion of the aorta in experimental cardiopulmonary resuscitation: Aortic occlusion level matters. Shock, 45(2), 205-212.
Haywood, K., Whitehead, L., Nadkarni, V. M., Achana, F., Beesems, S., Böttiger, B. W., et al. (2018). COSCA: Core Outcome Set for Cardiac Arrest in adults. Circulation, 137(22), e783-e801.
Jansen, J. O., Hudson, J., Cochran, C., et al. (2023). Emergency department resuscitative endovascular balloon occlusion of the aorta in trauma patients with exsanguinating hemorrhage: The UK-REBOA randomized clinical trial. JAMA, 330(19), 1862-1871.
Kim HE, Chu SE, Jo YH, Chiang WC, Jang DH, Chang CH, Oh SH, Chen HA, Park SM, Sun JT, Lee DK. Effect of resuscitative endovascular balloon occlusion of the aorta in nontraumatic out-of-hospital cardiac arrest: a multinational, multicenter, randomized, controlled trial. Trials. 2024 Feb 13;25(1):118. doi: 10.1186/s13063-024-07928-x.
Meaney, P. A., Bobrow, B. J., Mancini, M. E., Christenson, J., de Caen, A. R., Bhanji, F., et al. (2013). Cardiopulmonary resuscitation quality: Improving cardiac resuscitation outcomes both inside and outside the hospital. Circulation, 128(4), 417-435.
Paradis, N. A., Martin, G. B., Rivers, E. P., Goetting, M. G., Appleton, T. J., Feingold, M., & Nowak, R. M. (1990). Coronary perfusion pressure and the return of spontaneous circulation in human cardiopulmonary resuscitation. JAMA, 263(8), 1106-1113.
U.S. Food and Drug Administration. (2017). ER-REBOA catheter 510(k) summary, K170411.
Recent Articles
Integrative Perspectives on Cognition, Emotion, and Digital Behavior
Sleep-related:
Longevity/Nutrition & Diet:
Philosophical / Happiness / Social:
Other:
Modern Mind Unveiled
Developed under the direction of David McAuley, Pharm.D., this collection explores what it means to think, feel, and connect in the modern world. Drawing upon decades of clinical experience and digital innovation, Dr. McAuley and the GlobalRPh initiative translate complex scientific ideas into clear, usable insights for clinicians, educators, and students.
The series investigates essential themes–cognitive bias, emotional regulation, digital attention, and meaning-making—revealing how the modern mind adapts to information overload, uncertainty, and constant stimulation.
At its core, the project reflects GlobalRPh’s commitment to advancing evidence-based medical education and clinical decision support. Yet it also moves beyond pharmacotherapy, examining the psychological and behavioral dimensions that shape how healthcare professionals think, learn, and lead.
Through a synthesis of empirical research and philosophical reflection, Modern Mind Unveiled deepens our understanding of both the strengths and vulnerabilities of the human mind. It invites readers to see medicine not merely as a science of intervention, but as a discipline of perception, empathy, and awareness–an approach essential for thoughtful practice in the 21st century.
The Six Core Themes
I. Human Behavior and Cognitive Patterns
Examining the often-unconscious mechanisms that guide human choice-how we navigate uncertainty, balance logic with intuition, and adapt through seemingly irrational behavior.
II. Emotion, Relationships, and Social Dynamics
Investigating the structure of empathy, the psychology of belonging, and the influence of abundance and selectivity on modern social connection.
III. Technology, Media, and the Digital Mind
Analyzing how digital environments reshape cognition, attention, and identity- exploring ideas such as gamification, information overload, and cognitive “nutrition” in online spaces.
IV. Cognitive Bias, Memory, and Decision Architecture
Exploring how memory, prediction, and self-awareness interact in decision-making, and how external systems increasingly serve as extensions of thought.
V. Habits, Health, and Psychological Resilience
Understanding how habits sustain or erode well-being-considering anhedonia, creative rest, and the restoration of mental balance in demanding professional and personal contexts.
VI. Philosophy, Meaning, and the Self
Reflecting on continuity of identity, the pursuit of coherence, and the construction of meaning amid existential and informational noise.
Keywords
Cognitive Science • Behavioral Psychology • Digital Media • Emotional Regulation • Attention • Decision-Making • Empathy • Memory • Bias • Mental Health • Technology and Identity • Human Behavior • Meaning-Making • Social Connection • Modern Mind
Video Section
